Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Increased mean platelet volume and immature platelet fraction as potential predictors of thrombotic complications in BCR/ABL-negative myeloproliferative neoplasms

J. Kissova, A. Bulikova, P. Ovesna, L. Bourkova, M. Penka,

. 2014 ; 100 (5) : 429-36. [pub] 20140917

Language English Country Japan

Document type Journal Article, Research Support, Non-U.S. Gov't

E-resources Online Full text

NLK ProQuest Central from 2001-01-01 to 1 year ago
Medline Complete (EBSCOhost) from 2011-01-01 to 1 year ago
Nursing & Allied Health Database (ProQuest) from 2001-01-01 to 1 year ago
Health & Medicine (ProQuest) from 2001-01-01 to 1 year ago

BCR/ABL-negative myeloproliferative neoplasms (MPNs) are considered to be acquired thrombophilic conditions. Persistently enhanced platelet activation has been described in polycythaemia vera and essential thrombocythaemia (ET), and shown to contribute to a higher risk of arterial and venous thrombotic complications. Recent studies have shown that mean platelet volume (MPV) and immature platelet fraction (IPF) can serve as useful markers of platelet activation and increased risk of thrombosis. The aim of the present study was to investigate the relationship between these parameters and thrombotic events in BCR/ABL-negative MPN. MPV values in patients with BCR/ABL-negative MPN were significantly higher than MPV values of healthy individuals (P < 0.001). No significant difference in MPV or IPF was observed between groups of patients with and without thrombotic complications (P = 0.441; P = 0.110); the difference in IPF values was close to the significance level for patients with ET (P = 0.073). Higher values of IPF were more frequently detected in patients with JAK2 V617F positivity (P = 0.030). These patients had higher MPV more frequently than others, and this difference was close to the significance level (P = 0.056). Further studies should validate the use of platelet parameters to identify patients at high risk.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc15031853
003      
CZ-PrNML
005      
20151013103745.0
007      
ta
008      
151005s2014 ja f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s12185-014-1673-0 $2 doi
035    __
$a (PubMed)25227185
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ja
100    1_
$a Kissova, Jarmila $u Department of Haematology, University Hospital Brno, Jihlavska 20, 625 00, Brno, Czech Republic, jkissova@fnbrno.cz.
245    10
$a Increased mean platelet volume and immature platelet fraction as potential predictors of thrombotic complications in BCR/ABL-negative myeloproliferative neoplasms / $c J. Kissova, A. Bulikova, P. Ovesna, L. Bourkova, M. Penka,
520    9_
$a BCR/ABL-negative myeloproliferative neoplasms (MPNs) are considered to be acquired thrombophilic conditions. Persistently enhanced platelet activation has been described in polycythaemia vera and essential thrombocythaemia (ET), and shown to contribute to a higher risk of arterial and venous thrombotic complications. Recent studies have shown that mean platelet volume (MPV) and immature platelet fraction (IPF) can serve as useful markers of platelet activation and increased risk of thrombosis. The aim of the present study was to investigate the relationship between these parameters and thrombotic events in BCR/ABL-negative MPN. MPV values in patients with BCR/ABL-negative MPN were significantly higher than MPV values of healthy individuals (P < 0.001). No significant difference in MPV or IPF was observed between groups of patients with and without thrombotic complications (P = 0.441; P = 0.110); the difference in IPF values was close to the significance level for patients with ET (P = 0.073). Higher values of IPF were more frequently detected in patients with JAK2 V617F positivity (P = 0.030). These patients had higher MPV more frequently than others, and this difference was close to the significance level (P = 0.056). Further studies should validate the use of platelet parameters to identify patients at high risk.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    12
$a trombocyty $x metabolismus $x patologie $7 D001792
650    _2
$a studie případů a kontrol $7 D016022
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a bcr-abl fúzní proteiny $x genetika $7 D016044
650    _2
$a lidé $7 D006801
650    _2
$a Janus kinasa 2 $x genetika $7 D053614
650    _2
$a mužské pohlaví $7 D008297
650    12
$a střední objem trombocytu $7 D063847
650    _2
$a lidé středního věku $7 D008875
650    _2
$a mutace $7 D009154
650    _2
$a myeloproliferativní poruchy $x komplikace $x diagnóza $x genetika $7 D009196
650    _2
$a inhibitory agregace trombocytů $x terapeutické užití $7 D010975
650    _2
$a chinazoliny $x terapeutické užití $7 D011799
650    _2
$a rizikové faktory $7 D012307
650    _2
$a trombóza $x krev $x farmakoterapie $x etiologie $7 D013927
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Bulikova, Alena
700    1_
$a Ovesna, Petra
700    1_
$a Bourkova, Ludmila
700    1_
$a Penka, Miroslav
773    0_
$w MED00002329 $t International journal of hematology $x 1865-3774 $g Roč. 100, č. 5 (2014), s. 429-36
856    41
$u https://pubmed.ncbi.nlm.nih.gov/25227185 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20151005 $b ABA008
991    __
$a 20151013103935 $b ABA008
999    __
$a ok $b bmc $g 1092729 $s 914979
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2014 $b 100 $c 5 $d 429-36 $e 20140917 $i 1865-3774 $m International journal of hematology $n Int J Hematol $x MED00002329
LZP    __
$a Pubmed-20151005

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...